Bacteriophage lysins for Bacillus anthracis
US8389469B2 · kind B2 · utility
2Cited by
23References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 31, 2006 |
| Grant date | Mar 5, 2013 |
| Priority date | — |
| Expiry date | Jun 11, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to methods, compositions and articles of manufacture useful for the treatment of Bacillus anthracis and B. cereus bacteria and spores, and related conditions. The disclosure further relates to compositions comprising various phage associated lytic enzyme that rapidly and specifically detect and kill Bacillus anthracis and other bacteria. Related articles of manufacture, methods of degrading spores and methods of treatment of infections or bacteria populations of, or subjects exposed to or at risk for exposure to Bacillus anthracis are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.